# A multi-omics approach elucidates the link between artificial food colorings and common cancers

**Authors:** Xiang Feng, Biyuan Luo, Mengge Ding, Xianling Liu

PMC · DOI: 10.3389/fnut.2026.1743416 · Frontiers in Nutrition · 2026-02-05

## TL;DR

This study explores how artificial food colorings might be linked to cancer by analyzing molecular networks and patient outcomes.

## Contribution

The study integrates multi-omics data to reveal novel associations between artificial food colorings and cancer-related molecular mechanisms and prognosis.

## Key findings

- 108 shared targets were identified linking artificial food colorings and cancer, with 50 prioritized as core targets.
- Key pathways like cell-cycle regulation and PI3K–Akt signaling were enriched in cancer-related networks.
- TCGA-derived signatures predicted survival differences, and in vivo experiments showed accelerated tumor growth with AFC exposure.

## Abstract

Artificial food colorings (AFCs) are widely used, yet their potential links to cancer remain unclear. We investigated associations between commonly used AFCs and cancer-related molecular networks and prognosis.

AFCs-related targets were collected from CTD, ChEMBL, SEA, and TargetNet, and cancer-related targets from GeneCards, OMIM, and CTD. Overlapping targets were subjected to STRING-based PPI analysis and Cytoscape visualization, followed by GO/KEGG enrichment. Core targets were evaluated for differential expression in GEO datasets of non-small cell lung cancer (NSCLC), colon adenocarcinoma (COAD), gastric cancer (GC), and breast cancer (BRCA), with GSEA for pathway characterization. Expression patterns were examined using GEPIA2. TCGA transcriptomic and clinical data were used to construct prognostic models via univariate Cox regression, LASSO selection, and multivariate Cox regression. Key genes were assessed using the Human Protein Atlas (HPA) and qPCR, and in vivo experiments evaluated tumor growth under AFCs exposure.

Four high-exposure AFCs were analyzed. We identified 108 shared AFCs–cancer targets and prioritized 50 core targets. Enrichment analyses highlighted cancer-relevant functional themes, including cell-cycle regulation (cyclin-dependent protein kinase holoenzyme complex) and oncogenic signaling (PI3K–Akt pathway). Multiple core targets were dysregulated in GEO tumor datasets, and GSEA identified consistently enriched pathways across cancer types. TCGA-derived signatures stratified patients into distinct risk groups with significantly different overall survival. HPA supported protein-level differences for selected targets, qPCR indicated that Allura Red AC or Tartrazine modulated prognostic gene expression in cancer cell lines, and AFCs exposure was associated with accelerated LLC tumor growth in mice.

This integrative analysis suggests that commonly used AFCs may be associated with cancer-related molecular networks and adverse prognosis in NSCLC, COAD, GC, and BRCA, informing future safety evaluation and regulation.

## Linked entities

- **Chemicals:** Allura Red AC (PubChem CID 33258), Tartrazine (PubChem CID 164825)
- **Diseases:** non-small cell lung cancer (MONDO:0005233), colon adenocarcinoma (MONDO:0002271), gastric cancer (MONDO:0001056), breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** MIR433 (microRNA 433) [NCBI Gene 574034] {aka MIRN433, hsa-mir-433, miRNA433, mir-433}, CCND1 (cyclin D1) [NCBI Gene 595] {aka BCL1, D11S287E, PRAD1, U21B31}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, GSTM1 (glutathione S-transferase mu 1) [NCBI Gene 2944] {aka GST1, GSTM1-1, GSTM1a-1a, GSTM1b-1b, GTH4, GTM1}, SOD2 (superoxide dismutase 2) [NCBI Gene 6648] {aka GC1, GClnc1, IPO-B, IPOB, MNSOD, MVCD6}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, CDK4 (cyclin dependent kinase 4) [NCBI Gene 1019] {aka CMM3, MCPH31, PSK-J3}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, IL18 (interleukin 18) [NCBI Gene 3606] {aka IGIF, IL-18, IL-1g, IL1F4}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, NOS2 (nitric oxide synthase 2) [NCBI Gene 4843] {aka HEP-NOS, INOS, NOS, NOS2A}, BRCA1 (BRCA1 DNA repair associated) [NCBI Gene 672] {aka BRCAI, BRCC1, BROVCA1, FANCS, IRIS, PNCA4}, CDH1 (cadherin 1) [NCBI Gene 999] {aka Arc-1, BCDS1, CD324, CDHE, ECAD, LCAM}, DNMT1 (DNA methyltransferase 1) [NCBI Gene 1786] {aka ADCADN, AIM, CXXC9, DNMT, HSN1E, MCMT}, RRM2 (ribonucleotide reductase regulatory subunit M2) [NCBI Gene 6241] {aka C2orf48, R2, RR2, RR2M}, CYP19A1 (cytochrome P450 family 19 subfamily A member 1) [NCBI Gene 1588] {aka ARO, ARO1, CPV1, CYAR, CYP19, CYPXIX}, CDK6 (cyclin dependent kinase 6) [NCBI Gene 1021] {aka MCPH12, PLSTIRE}, CDK1 (cyclin dependent kinase 1) [NCBI Gene 983] {aka CDC2, CDC28A, P34CDC2}, CASP9 (caspase 9) [NCBI Gene 842] {aka APAF-3, APAF3, ICE-LAP6, MCH6, PPP1R56}, SMARCA4 (SWI/SNF related BAF chromatin remodeling complex subunit ATPase 4) [NCBI Gene 6597] {aka BAF190, BAF190A, BRG1, CSS4, MRD16, OTSC12}, PCNA (proliferating cell nuclear antigen) [NCBI Gene 5111] {aka ATLD2}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, HSD17B6 (hydroxysteroid 17-beta dehydrogenase 6) [NCBI Gene 8630] {aka HSE, RODH, SDR9C6}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, FXYD3 (FXYD domain containing ion transport regulator 3) [NCBI Gene 5349] {aka MAT8, PLML}, RELA (RELA proto-oncogene, NF-kB subunit) [NCBI Gene 5970] {aka AIF3BL3, CMCU, NFKB3, p65}, PPARG (peroxisome proliferator activated receptor gamma) [NCBI Gene 5468] {aka CIMT1, FPLD3, GLM1, NR1C3, PPARG1, PPARG2}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, AKR1C1 (aldo-keto reductase family 1 member C1) [NCBI Gene 1645] {aka 2-ALPHA-HSD, 20-ALPHA-HSD, DD1, DD1/DD2, DDH, DDH1}, GRIN2B (glutamate ionotropic receptor NMDA type subunit 2B) [NCBI Gene 2904] {aka DEE27, EIEE27, GluN2B, MRD6, NMDAR2B, NR2B}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}, CYP3A4 (cytochrome P450 family 3 subfamily A member 4) [NCBI Gene 1576] {aka CP33, CP34, CYP3A, CYP3A3, CYPIIIA3, CYPIIIA4}, SHROOM4 (shroom family member 4) [NCBI Gene 57477] {aka MRXSSDS, SHAP, shrm4}, GPER1 (G protein-coupled estrogen receptor 1) [NCBI Gene 2852] {aka CEPR, CMKRL2, DRY12, FEG-1, GPCR-Br, GPER}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, CYP1A1 (cytochrome P450 family 1 subfamily A member 1) [NCBI Gene 1543] {aka AHH, CP11, CYP1, CYPIA1, P1-450, P450-C}, GSTA4 (glutathione S-transferase alpha 4) [NCBI Gene 2941] {aka GSTA4-4, GTA4}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, CDK2 (cyclin dependent kinase 2) [NCBI Gene 1017] {aka CDKN2, p33(CDK2)}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, FOXO1 (forkhead box O1) [NCBI Gene 2308] {aka FKH1, FKHR, FOXO1A}, DCN (decorin) [NCBI Gene 1634] {aka CSCD, DSPG2, PG40, PGII, PGS2, SLRR1B}, TSC2 (TSC complex subunit 2) [NCBI Gene 7249] {aka LAM, PPP1R160, TSC4}, KDM5A (lysine demethylase 5A) [NCBI Gene 5927] {aka NEDEHC, RBBP-2, RBBP2, RBP2}, GRIN2A (glutamate ionotropic receptor NMDA type subunit 2A) [NCBI Gene 2903] {aka EPND, FESD, GluN2A, LKS, NMDAR2A, NR2A}, SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}, NR4A1 (nuclear receptor subfamily 4 group A member 1) [NCBI Gene 3164] {aka GFRP1, HMR, N10, NAK-1, NGFIB, NP10}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}, CYP1B1 (cytochrome P450 family 1 subfamily B member 1) [NCBI Gene 1545] {aka ASGD6, CP1B, CYPIB1, GLC3A, P4501B1}, CYP1A2 (cytochrome P450 family 1 subfamily A member 2) [NCBI Gene 1544] {aka CP12, CYPIA2, P3-450, P450(PA)}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, CYP4F3 (cytochrome P450 family 4 subfamily F member 3) [NCBI Gene 4051] {aka CPF3, CYP4F, CYPIVF3, LTB4H}, PTGS2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 5743] {aka COX-2, COX2, GRIPGHS, PGG/HS, PGHS-2, PHS-2}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}
- **Diseases:** hyperactivity (MESH:D006948), esophageal cancer (MESH:D004938), immune dysregulation (OMIM:614878), OS (MESH:C567932), COAD (MESH:D003110), glioblastoma (MESH:D005909), head and neck squamous cell carcinoma (MESH:D000077195), NSCLC (MESH:D002289), GC (MESH:D013274), IBD (MESH:D015212), lung adenocarcinoma (MESH:D000077192), BRCA (MESH:D001943), HPA (MESH:C483996), LLC (MESH:D018827), hepatocellular carcinogenesis (MESH:D063646), neurofunctional impairment (MESH:C564098), learning difficulties (MESH:D007859), ACF-cancer (MESH:D009369), AFCs (MESH:D003117), colitis (MESH:D003092), ADHD (MESH:D001289), Alzheimer's disease (MESH:D000544), neurotoxicity (MESH:D020258), lung cancer (MESH:D008175), XL (MESH:D000080345), toxicity (MESH:D064420), melanoma (MESH:D008545), metastasis (MESH:D009362), inflammation (MESH:D007249), colon cancer (MESH:D015179), carcinogenic (MESH:D011230), melanosis coli (MESH:D008548)
- **Chemicals:** Erythrosine (MESH:D004923), Sunset Yellow FCF (MESH:C005842), hydrogen (MESH:D006859), drinking water (MESH:D060766), Sudan I (MESH:C024336), PBS (MESH:D007854), alpha-linolenic acid (MESH:D017962), CO2 (MESH:D002245), beta-alanine (MESH:D015091), tyrosine (MESH:D014443), water (MESH:D014867), ribociclib (MESH:C000589651), Allura Red AC (MESH:C005915), cysteine (MESH:D003545), histidine (MESH:D006639), Brilliant Blue (MESH:C006796), streptomycin (MESH:D013307), arginine (MESH:D001120), fatty acid (MESH:D005227), propanoate (MESH:D011422), proline (MESH:D011392), linoleic acid (MESH:D019787), methionine (MESH:D008715), AFCs (-), Tartrazine (MESH:D013645), penicillin (MESH:D010406)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** serine/threonine, rs28757157
- **Cell lines:** MCF-7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031), AGS — Homo sapiens (Human), Gastric adenocarcinoma, Cancer cell line (CVCL_0139), HCT116 — Homo sapiens (Human), Colon carcinoma, Cancer cell line (CVCL_0291), LLC — Mus musculus (Mouse), Malignant tumors of the mouse pulmonary system, Cancer cell line (CVCL_4358), C57BL/6 — Mus musculus (Mouse), Transformed cell line (CVCL_C0MU), A549 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12916573/full.md

## Figures

13 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12916573/full.md

## References

59 references — full list in the complete paper: https://tomesphere.com/paper/PMC12916573/full.md

---
Source: https://tomesphere.com/paper/PMC12916573